How to run a more efficient pediatric clinical trial: Although pediatric trials overall cost roughly the same as adult clinical trials according to one analysis, they generally produce a more modest return on investment. To ensure your neurodevelopmental or other pediatric study completes in a cost-effective, efficient manner, follow these tips:
C3 glomerulopathy (C3G), a rare kidney disease, affects only two or three people out of every one million. That’s only a couple people out of the entire population of San Jose, California or Austin, Texas. Although C3G only affects a select few, without treatment it can lead to severe kidney damage and failure, necessitating expensive dialysis or transplant. To date, there is no specific, effective therapy. As a CRO that understands the challenges involved in researching rare disease treatments, we’re here to help drug developers deliver the most effective clinical trials possible—on time and on budget. Speak with one of our rare disease experts today to find out how we can help you develop your next rare disease program.
Why Do So Many Clinical Trials Fall Behind? Clinical trials are not immune to missed deadlines and cost overruns. However, with proper advance planning, you can up the odds of success and avoid major glitches. Our studies show that about 33% of all clinical trials are behind schedule at any given moment. These trials under-perform due to operational failures; meaning, they’re behind schedule, over budget, or the data produced lacks the quality needed to support an approval.
Movement disorders such as Parkinson’s disease, ataxias, tremor, dystonia, tics, Tourette’s, and dozens of rare diseases, […]
Eczema affects more people in the United States than diabetes (10.1 vs. 9.4 million)1,2. More than […]
In our rescue white paper, 3 Measures to Overcome Operational Failures, we explain our ROI concept. Early in a trial, intervention provides dramatic benefits for minimal cost. An assessment or review may be all that’s needed to get a study back on track.
Less than a year ago, FDA approved the first cannabinoid-derived drug, Epidiolex. It’s a […]
Each year, doctors diagnose about 1,000 Americans with cystic fibrosis, a rare hereditary disease that affects […]
“Microbiome” has become a consumer product buzzword, found in advertisements for soap and dozens […]
The numbers vary but multiple surveys confirm what we all know: patient recruitment is […]
Neurological disorders and diseases affect all ages and ethnicities, and most result in long-term disability […]
In a statement last August, departing FDA Commissioner Scott Gottlieb outlined several steps the […]